An Update on the Johnson and Johnson VaccineDepartment of Health and Human Services
As of April 12, nearly seven (7) million J&J doses have been administered. The U.S. Center for Diseases Control and Prevention (CDC) and the U.S. Food & Drug Administration (FDA) are investigating six (6) cases of an extremely rare type of blood clot in individuals after receiving the J&J vaccine.
As CDC and FDA noted in join their statement, right now these adverse events appear to be extremely rare.
Out of an abundance of caution, and as they review these rare cases, CDC and FDA are recommending vaccine providers pause on administering the J&J vaccine. As FDA noted this morning, FDA and CDC hope to review this quickly over the next few days. This pause is important so that we have time to review the cases and help healthcare providers understand how to treat any individuals who may experience these rare events.
This announcement will not have a significant impact on our vaccination plan: J&J vaccine makes up less than five (5) percent of the recorded shots in arms in the United States to date.
Based on actions taken by the President earlier this year, the U.S. has secured enough Pfizer and Moderna doses for 300 million Americans. You can read the full statement from White House COVID-19 Response Coordinator, Jeff Zients, on the impact on supply here.